Vogivoc-GM2/0.3 Tablets

Vogivoc-GM2/0.3 is a triple combination tablet designed for comprehensive management of type 2 diabetes mellitus. It combines Glimepiride, a sulfonylurea that stimulates insulin secretion; Metformin Hydrochloride (SR), which improves insulin sensitivity and reduces glucose production; and Voglibose, an alpha-glucosidase inhibitor that delays carbohydrate absorption. Together, these agents work synergistically to improve blood sugar control throughout the day.

Benefits:

• Comprehensive blood sugar management: Controls fasting, postprandial, and overall blood glucose levels.

• Improves insulin sensitivity: Metformin helps the body use insulin more effectively.

• Stimulates insulin secretion: Glimepiride enhances insulin release from the pancreas.

• Reduces carbohydrate absorption: Voglibose prevents sharp spikes after meals.

• Sustained release formulation: Provides prolonged action with better tolerance and fewer side effects.

• Manufactured under GMP and ISO standards: Ensures safety, efficacy, and quality.

Dosage:

• Take as directed by your healthcare provider.

• Usually administered once or twice daily, preferably before meals.

Why Cardiever?

• High-quality manufacturing: Produced under stringent GMP and ISO certifications.

• Trusted diabetes care: Focus on effective and safe diabetes management solutions.

• Affordable and accessible: Quality medications at competitive prices.

• Reliable supply: Consistent availability to support ongoing therapy.

• Expert-backed: Developed by experienced pharmaceutical professionals committed to patient health.